X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA GLENMARK PHARMA ALEMBIC PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 26.9 14.1 191.5% View Chart
P/BV x 6.1 3.9 156.0% View Chart
Dividend Yield % 0.8 0.3 237.7%  

Financials

 ALEMBIC PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
GLENMARK PHARMA
Mar-16
ALEMBIC PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs7921,262 62.7%   
Low Rs443672 66.0%   
Sales per share (Unadj.) Rs167.0270.6 61.7%  
Earnings per share (Unadj.) Rs38.224.9 153.4%  
Cash flow per share (Unadj.) Rs42.034.4 122.0%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.2 313.2%  
Book value per share (Unadj.) Rs84.9151.3 56.1%  
Shares outstanding (eoy) m188.52282.16 66.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.73.6 103.4%   
Avg P/E ratio x16.238.9 41.6%  
P/CF ratio (eoy) x14.728.1 52.3%  
Price / Book Value ratio x7.36.4 113.8%  
Dividend payout %10.58.0 130.4%   
Avg Mkt Cap Rs m116,383272,778 42.7%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m4,21413,782 30.6%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m31,48776,340 41.2%  
Other income Rs m55356 15.5%   
Total revenues Rs m31,54276,696 41.1%   
Gross profit Rs m10,06014,172 71.0%  
Depreciation Rs m7222,691 26.8%   
Interest Rs m371,789 2.1%   
Profit before tax Rs m9,35610,048 93.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1603,028 71.3%   
Profit after tax Rs m7,1947,019 102.5%  
Gross profit margin %31.918.6 172.1%  
Effective tax rate %23.130.1 76.6%   
Net profit margin %22.89.2 248.5%  
BALANCE SHEET DATA
Current assets Rs m15,06659,096 25.5%   
Current liabilities Rs m7,67440,018 19.2%   
Net working cap to sales %23.525.0 93.9%  
Current ratio x2.01.5 132.9%  
Inventory Days Days6775 89.3%  
Debtors Days Days41119 34.1%  
Net fixed assets Rs m8,23739,075 21.1%   
Share capital Rs m377282 133.6%   
"Free" reserves Rs m15,41630,281 50.9%   
Net worth Rs m16,00542,703 37.5%   
Long term debt Rs m024,873 0.0%   
Total assets Rs m24,594111,026 22.2%  
Interest coverage x255.26.6 3,857.6%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.30.7 186.2%   
Return on assets %29.47.9 370.6%  
Return on equity %44.916.4 273.5%  
Return on capital %58.717.5 335.0%  
Exports to sales %55.743.3 128.8%   
Imports to sales %10.47.4 140.3%   
Exports (fob) Rs m17,55133,044 53.1%   
Imports (cif) Rs m3,2835,672 57.9%   
Fx inflow Rs m17,81136,945 48.2%   
Fx outflow Rs m5,31861,066 8.7%   
Net fx Rs m12,493-24,122 -51.8%   
CASH FLOW
From Operations Rs m9,3043,449 269.8%  
From Investments Rs m-3,105-8,802 35.3%  
From Financial Activity Rs m-1,9596,986 -28.0%  
Net Cashflow Rs m4,240934 454.1%  

Share Holding

Indian Promoters % 74.1 48.3 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 6.9 42.0%  
FIIs % 9.1 34.4 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 56,727 87.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Aug 17, 2017 01:39 PM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS